ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

NCI Finds Physician Recommendation Drives Patient Demand For ABMT

July 19, 1996

FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment.

September 28, 2001

O’Leary Leads RPCI’s OR;

February 8, 2002

In Brief: Morgan Named Director Of UAMS Myeloma Institute

April 25, 2014

In Brief: House Committee Approves Funding Boost For NIH; Michigan Centers Receive $15M Gift

July 28, 1995

McKay Retires As Fox Chase Executive, Is Succeeded By Donald Leedy As VP.

June 2, 2000